Soleno Therapeutics (SLNO) Non-cash Items (2017 - 2026)

Soleno Therapeutics (SLNO) has 10 years of Non-cash Items data on file, last reported at $103.6 million in Q1 2026.

• Non-cash Items for Q1 2026 came in at $103.6 million, down 20.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $103.6 million (down 20.3% YoY), and the FY2025 annual result was $47.4 million, down 40.42% from the prior year.
• Non-cash Items climbed to $103.6 million in Q1 2026 per SLNO's latest filing, from $47.4 million in the prior quarter.
• Over five years, Non-cash Items peaked at $130.0 million in Q1 2025 and troughed at $3.2 million in Q4 2022.
• A 5-year average of $55.4 million and a median of $70.1 million in 2024 frame the typical range for Non-cash Items.
• The sharpest annual moves came in 2024 and 2025: Non-cash Items surged 2358.16% in 2024, then sank 40.42% in 2025.
• A 5-year view of Non-cash Items shows it stood at $3.2 million in 2022, then jumped by 2113.56% to $70.8 million in 2023, then gained by 12.34% to $79.6 million in 2024, then tumbled by 40.42% to $47.4 million in 2025, then surged by 118.5% to $103.6 million in 2026.
• Business Quant data shows SLNO's Non-cash Items at $103.6 million in Q1 2026, $47.4 million in Q4 2025, and $113.6 million in Q3 2025.